SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 693.35-0.2%Nov 14 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (2548)10/25/2018 4:34:15 PM
From: Miljenko Zuanic  Read Replies (1) of 3559
 
<When the prefilled syringe is available, the question is: What % of Eylea Medicare patients will be able to obtain the prefilled syringe under Part D (rather than Part B) and pay a separate physician fee for the injection?>

I did not know that preffiled syringe is PartD drug. Did Roche/Novartis cut price down, for Lucentis preffiled syringe. I remember them talking about increased rebate/discount, but did not have idea from where originated?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News